Amgen Inc (AMGN) 159.85 $AMGN
3 Top-Rated Biotechs Could Take Buy Points Soon
at Investor's Business Daily - 22 mins ago
Three highly rated stocks in the No. 1 Biomed/Biotech industry group are getting close to buy points: Ligand Pharmaceuticals (LGND), Amgen (AMGN) and Alexion Pharmaceuticals (ALXN). Watch this video to find out what their buy points are -- you may...
ALXN: 173.30 (-6.96), AMGN: 159.85 (-4.45), LGND: 77.11 (+0.88)
Final Glance: Biotechnology companies
AP - 39 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 98.13 (-2.56), AMGN: 159.85 (-4.45), CELG: 115.28 (-4.74)
Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 43 mins ago
Amgen's (AMGN) multiple myeloma drug, Kyprolis has been granted priority review in the U.S. for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
CYTK: 6.78 (-0.32), HZNP: 25.97 (+0.19), AMGN: 159.85 (-4.45), ACOR: 33.28 (-0.63)
Midday Glance: Biotechnology companies
AP - Tue Mar 31, 1:48PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 98.13 (-2.56), AMGN: 159.85 (-4.45), CELG: 115.28 (-4.74)
Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 422.24 (-9.38), ICPT: 282.02 (-13.89), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26)
Early Glance: Biotechnology companies
AP - Tue Mar 31, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 98.13 (-2.56), AMGN: 159.85 (-4.45), CELG: 115.28 (-4.74)
How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.95 (+0.25), AMGN: 159.85 (-4.45), MNTA: 15.20 (+0.02), NVS: 98.61 (-2.70), CHRS: 30.58 (+0.56)
End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cr7mzg/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" report to their offering. End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" provides data on the End-Stage Kidney Disease (end-stage renal disease or ESRD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating End-Stage Kidney Disease (end-stage renal disease or ESRD). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in End-Stage Kidney Disease (end-stage renal disease or ESRD) Therapeutics Clinical Trials - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Pfizer Inc. - Sanofi - Shire Plc - Merck & Co., Inc. - Baxter International Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/cr...age_kidney
BAX: 68.50 (-0.26), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), MRK: 57.48 (-0.86), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
'Fast Money' Recap: A Stock Rally With 'Window Dressing'
at The Street - Tue Mar 31, 4:00AM CDT
The trading panel discussed volatility, GoPro and biotech stocks.
TSLA: 188.77 (-1.80), GPRO: 43.41 (-0.17), SPY: 206.43 (-1.82), GILD: 98.13 (-2.56), C: 51.52 (-0.12), IBB: 343.43 (-7.89), AMGN: 159.85 (-4.45), IWM: 124.37 (-0.40), IYT: 156.62 (-0.84), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74)
Renal Failure Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frs3p/renal_failure) has announced the addition of the "Renal Failure Global Clinical Trials Review, H1, 2015" report to their offering. Renal Failure Global Clinical Trials Review, H1, 2015 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Failure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Renal Failure Therapeutics Clinical Trials - Sanofi - Amgen Inc. - F. Hoffmann-La Roche Ltd. - Novartis AG - AbbVie Inc. - Pfizer Inc. - AstraZeneca PLC - Shire Plc - Abbott Laboratories - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/8f...al_failure
JNJ: 100.60 (-0.95), ABT: 46.33 (-0.75), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
PR Newswire - Mon Mar 30, 3:07PM CDT
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the Goldman Sachs Conference Center in New York City. Scott Foraker, vice president and general manager of biosimilars at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 159.85 (-4.45)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), CLLS: 34.58 (-0.62), XON: 45.37 (-0.93), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09)
60 minutes piece highlights promise of cancer-killing viruses
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 11:30AM CDT
ONCY: 0.74 (-0.03), AMGN: 159.85 (-4.45)
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:30AM CDT
Hospira, Inc. presented data from two studies on a proposed biosimilar, Retacrit.
JNJ: 100.60 (-0.95), ALNY: 104.42 (-3.36), PFE: 34.79 (-0.21), AMGN: 159.85 (-4.45), HSP: 87.84 (+0.12)
FDA accepts Amgen's Kyprolis sNDA under Priority Review
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 9:18AM CDT
AMGN: 159.85 (-4.45)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), HD: 113.61 (-1.02), RYL: 48.74 (-0.17), ALTR: 42.91 (+0.09), AMGN: 159.85 (-4.45), XOM: 85.00 (-0.63), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74), LEN: 51.81 (+0.32), CVX: 104.98 (-1.92), TOL: 39.34 (+0.13), REGN: 451.48 (-8.30)
FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
PR Newswire - Mon Mar 30, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the conversion of accelerated approval to full approval and expand the current Kyprolis indication. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015.
AMGN: 159.85 (-4.45)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38), AMGN: 159.85 (-4.45)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 422.24 (-9.38), GE: 24.81 (-0.31), PCYC: 255.95 (-0.48), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), HON: 104.31 (-0.60), KRFT: 87.11 (-3.50), INTC: 31.27 (-0.19), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), KMX: 69.01 (-0.21), JACK: 95.92 (-1.12), YHOO: 44.43 (-0.52), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), ABBV: 58.54 (+0.30), REGN: 451.48 (-8.30), UNP: 108.31 (-1.78), DK: 39.75 (-0.16), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), AMGN: 159.85 (-4.45), NXPI: 100.36 (-2.07), BA: 150.08 (-2.62), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), HAIN: 64.05 (-0.23), WWAV: 44.34 (-0.30), ZOES: 33.29 (+0.37), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), CNI: 66.87 (+0.64), NDLS: 17.44 (-0.10), MCD: 97.44 (-0.44), AVGO: 126.98 (-3.57)
3 Top-Rated Biotechs Could Take Buy Points Soon
at Investor's Business Daily - 22 mins ago
Three highly rated stocks in the No. 1 Biomed/Biotech industry group are getting close to buy points: Ligand Pharmaceuticals (LGND), Amgen (AMGN) and Alexion Pharmaceuticals (ALXN). Watch this video to find out what their buy points are -- you may...
ALXN: 173.30 (-6.96), AMGN: 159.85 (-4.45), LGND: 77.11 (+0.88)
Final Glance: Biotechnology companies
AP - 39 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 98.13 (-2.56), AMGN: 159.85 (-4.45), CELG: 115.28 (-4.74)
Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 43 mins ago
Amgen's (AMGN) multiple myeloma drug, Kyprolis has been granted priority review in the U.S. for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
CYTK: 6.78 (-0.32), HZNP: 25.97 (+0.19), AMGN: 159.85 (-4.45), ACOR: 33.28 (-0.63)
Midday Glance: Biotechnology companies
AP - Tue Mar 31, 1:48PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 98.13 (-2.56), AMGN: 159.85 (-4.45), CELG: 115.28 (-4.74)
Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 422.24 (-9.38), ICPT: 282.02 (-13.89), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26)
Early Glance: Biotechnology companies
AP - Tue Mar 31, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 98.13 (-2.56), AMGN: 159.85 (-4.45), CELG: 115.28 (-4.74)
How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.95 (+0.25), AMGN: 159.85 (-4.45), MNTA: 15.20 (+0.02), NVS: 98.61 (-2.70), CHRS: 30.58 (+0.56)
End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cr7mzg/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" report to their offering. End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" provides data on the End-Stage Kidney Disease (end-stage renal disease or ESRD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating End-Stage Kidney Disease (end-stage renal disease or ESRD). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in End-Stage Kidney Disease (end-stage renal disease or ESRD) Therapeutics Clinical Trials - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Pfizer Inc. - Sanofi - Shire Plc - Merck & Co., Inc. - Baxter International Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/cr...age_kidney
BAX: 68.50 (-0.26), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), MRK: 57.48 (-0.86), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
'Fast Money' Recap: A Stock Rally With 'Window Dressing'
at The Street - Tue Mar 31, 4:00AM CDT
The trading panel discussed volatility, GoPro and biotech stocks.
TSLA: 188.77 (-1.80), GPRO: 43.41 (-0.17), SPY: 206.43 (-1.82), GILD: 98.13 (-2.56), C: 51.52 (-0.12), IBB: 343.43 (-7.89), AMGN: 159.85 (-4.45), IWM: 124.37 (-0.40), IYT: 156.62 (-0.84), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74)
Renal Failure Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frs3p/renal_failure) has announced the addition of the "Renal Failure Global Clinical Trials Review, H1, 2015" report to their offering. Renal Failure Global Clinical Trials Review, H1, 2015 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Failure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Renal Failure Therapeutics Clinical Trials - Sanofi - Amgen Inc. - F. Hoffmann-La Roche Ltd. - Novartis AG - AbbVie Inc. - Pfizer Inc. - AstraZeneca PLC - Shire Plc - Abbott Laboratories - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/8f...al_failure
JNJ: 100.60 (-0.95), ABT: 46.33 (-0.75), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
PR Newswire - Mon Mar 30, 3:07PM CDT
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the Goldman Sachs Conference Center in New York City. Scott Foraker, vice president and general manager of biosimilars at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 159.85 (-4.45)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), CLLS: 34.58 (-0.62), XON: 45.37 (-0.93), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09)
60 minutes piece highlights promise of cancer-killing viruses
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 11:30AM CDT
ONCY: 0.74 (-0.03), AMGN: 159.85 (-4.45)
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:30AM CDT
Hospira, Inc. presented data from two studies on a proposed biosimilar, Retacrit.
JNJ: 100.60 (-0.95), ALNY: 104.42 (-3.36), PFE: 34.79 (-0.21), AMGN: 159.85 (-4.45), HSP: 87.84 (+0.12)
FDA accepts Amgen's Kyprolis sNDA under Priority Review
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 9:18AM CDT
AMGN: 159.85 (-4.45)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), HD: 113.61 (-1.02), RYL: 48.74 (-0.17), ALTR: 42.91 (+0.09), AMGN: 159.85 (-4.45), XOM: 85.00 (-0.63), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74), LEN: 51.81 (+0.32), CVX: 104.98 (-1.92), TOL: 39.34 (+0.13), REGN: 451.48 (-8.30)
FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
PR Newswire - Mon Mar 30, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the conversion of accelerated approval to full approval and expand the current Kyprolis indication. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015.
AMGN: 159.85 (-4.45)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38), AMGN: 159.85 (-4.45)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 422.24 (-9.38), GE: 24.81 (-0.31), PCYC: 255.95 (-0.48), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), HON: 104.31 (-0.60), KRFT: 87.11 (-3.50), INTC: 31.27 (-0.19), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), KMX: 69.01 (-0.21), JACK: 95.92 (-1.12), YHOO: 44.43 (-0.52), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), ABBV: 58.54 (+0.30), REGN: 451.48 (-8.30), UNP: 108.31 (-1.78), DK: 39.75 (-0.16), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), AMGN: 159.85 (-4.45), NXPI: 100.36 (-2.07), BA: 150.08 (-2.62), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), HAIN: 64.05 (-0.23), WWAV: 44.34 (-0.30), ZOES: 33.29 (+0.37), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), CNI: 66.87 (+0.64), NDLS: 17.44 (-0.10), MCD: 97.44 (-0.44), AVGO: 126.98 (-3.57)
